Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Recombinant antibody construct against human CD30 and CD16A

EU orphan designation number: EU/3/09/673   
Active ingredient: Recombinant antibody construct against human CD30 and CD16A
Indication: Treatment of Hodgkin lymphoma
Sponsor: Affimed GmbH
Im Neuenheimer Feld 582, 69120 Heidelberg, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/10/2009 Orphan designation EMEA/OD/046/09 (2009)7922 of 09/10/2009
22/01/2016 Change of name and/or address of sponsor